Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Non-Current Liabilities (2019 - 2025)

UroGen Pharma (URGN) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $302.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 3.89% year-over-year to $302.0 million, compared with a TTM value of $302.0 million through Dec 2025, up 3.89%, and an annual FY2025 reading of $302.0 million, up 3.89% over the prior year.
  • Total Non-Current Liabilities was $302.0 million for Q4 2025 at UroGen Pharma, up from $296.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $302.0 million in Q4 2025 and bottomed at $18.2 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $213.2 million, with a median of $231.7 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities soared 888.39% in 2022, then rose 3.89% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $108.5 million in 2021, then surged by 104.59% to $222.0 million in 2022, then rose by 8.27% to $240.3 million in 2023, then increased by 20.97% to $290.7 million in 2024, then rose by 3.89% to $302.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for URGN at $302.0 million in Q4 2025, $296.7 million in Q3 2025, and $298.3 million in Q2 2025.